Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024 07:00 ET
|
Travere Therapeutics, Inc.
FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss...